News
![BrainStorm](/sites/default/files/styles/x_large/public/2023-09/BrainStorm_Logo.jpg?itok=zxBPAwQa)
FDA advisors unconvinced by BrainStorm’s ALS cell therapy
An FDA advisory committee has voted by a huge margin that BrainStorm’s stem cell therapy for amyotrophic lateral sclerosis (ALS) – NurOwn – does not have enough data to su